The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source contract to 10X Genomics, Inc. for the procurement of specialized reagents necessary for a critical research project on the effects of SARS-CoV-2 on human brain tissues. The required products include proprietary kits such as the Dual Index Kit TS Set A and GEM-X Flex Gene Expression Kits, which are essential for isolating and amplifying RNA at the single-cell level, and are uniquely suited for the NIH's modified protocols compliant with Biosafety Level 3 requirements. This acquisition is crucial for maintaining the continuity of research and patient care, as any substitutions could lead to significant delays and require extensive re-validation. Interested parties capable of providing similar products may submit a capability statement to Tasha Lowe at lowet2@mail.nih.gov by June 21, 2025, at 3:00 PM EST.